Handel Gilead Sciences - GILD CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | 0.24 | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 1 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Gilead Sciences Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Nøglestatistikker
| Tidligere luk* | 77.23 |
| Åben* | 76.84 |
| 1-Års Ændring* | 29.91% |
| Dagens Spænd* | 76.49 - 77.51 |
| 52-Ugers Spænd | 57.17-89.74 |
| Gennemsnitlig Volumen (10 dage) | 6.95M |
| Gennemsnitlig Volumen (3 måneder) | 127.72M |
| Market Cap | 96.41B |
| P/E-forhold | 21.25 |
| Udestående aktier | 1.25B |
| Omsætning | 27.28B |
| EPS | 3.64 |
| Dividend (Udbytte %) | 3.88048 |
| Beta | 0.40 |
| Næste indtjeningsopgørelse | Apr 26, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|---|---|---|---|---|---|
| Mar 17, 2023 | 77.23 | -2.28 | -2.87% | 79.51 | 79.78 | 76.46 |
| Mar 16, 2023 | 78.98 | 0.19 | 0.24% | 78.79 | 79.88 | 77.74 |
| Mar 15, 2023 | 78.98 | -0.65 | -0.82% | 79.63 | 79.82 | 78.03 |
| Mar 14, 2023 | 78.62 | -0.12 | -0.15% | 78.74 | 79.83 | 78.24 |
| Mar 13, 2023 | 79.28 | -0.26 | -0.33% | 79.54 | 81.19 | 76.94 |
| Mar 10, 2023 | 79.00 | 0.48 | 0.61% | 78.52 | 80.24 | 77.61 |
| Mar 9, 2023 | 78.90 | -0.83 | -1.04% | 79.73 | 80.58 | 78.22 |
| Mar 8, 2023 | 79.73 | -0.36 | -0.45% | 80.09 | 80.68 | 79.48 |
| Mar 7, 2023 | 79.79 | -0.94 | -1.16% | 80.73 | 81.23 | 79.79 |
| Mar 6, 2023 | 81.04 | 0.27 | 0.33% | 80.77 | 81.25 | 80.35 |
| Mar 3, 2023 | 80.57 | 1.14 | 1.44% | 79.43 | 81.09 | 79.03 |
| Mar 2, 2023 | 79.43 | -0.05 | -0.06% | 79.48 | 79.83 | 78.44 |
| Mar 1, 2023 | 79.31 | -0.98 | -1.22% | 80.29 | 80.58 | 78.93 |
| Feb 28, 2023 | 79.96 | -0.55 | -0.68% | 80.51 | 80.92 | 79.28 |
| Feb 27, 2023 | 80.53 | 0.05 | 0.06% | 80.48 | 81.24 | 79.61 |
| Feb 24, 2023 | 80.59 | -1.69 | -2.05% | 82.28 | 82.49 | 80.13 |
| Feb 23, 2023 | 82.19 | -0.74 | -0.89% | 82.93 | 83.77 | 82.10 |
| Feb 22, 2023 | 82.93 | -1.75 | -2.07% | 84.68 | 84.83 | 82.93 |
| Feb 21, 2023 | 84.68 | 0.56 | 0.67% | 84.12 | 85.41 | 83.75 |
| Feb 17, 2023 | 84.35 | 1.17 | 1.41% | 83.18 | 85.18 | 81.65 |
Gilead Sciences Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| No events scheduled | ||
- Årlig
- Pr kvartal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total omsætning | 30390 | 26107 | 22127 | 22449 | 24689 | 27305 |
| Omsætning | 30390 | 26107 | 22127 | 22449 | 24689 | 27305 |
| Kost af omsætning, Total | 4261 | 4371 | 4853 | 4675 | 4572 | 6601 |
| Bruttofortjeneste | 26129 | 21736 | 17274 | 17774 | 20117 | 20704 |
| Totale Driftsudgifter | 12757 | 11983 | 13927 | 18162 | 20618 | 17387 |
| Salgs/Generelle/Admin. Udgifter, Total | 3398 | 3830 | 4056 | 4381 | 5151 | 5246 |
| Forskning & Udvikling | 4266 | 3512 | 4846 | 8934 | 10895 | 5540 |
| Usædvanlig Udgift (Indkomst) | 832 | 270 | 172 | 172 | ||
| Driftsindtægter | 17633 | 14124 | 8200 | 4287 | 4071 | 9918 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -790 | -1190 | -964 | 227 | -2684 | -1611 |
| Andre, Netto | 254 | 595 | 563 | 646 | 282 | -29 |
| Netto Indkomst Før Skat | 17097 | 13529 | 7799 | 5160 | 1669 | 8278 |
| Netto Indkomst Efter Skat | 13488 | 10136 | 5464 | 5364 | 89 | 6201 |
| Minoritetsrente | 13 | -16 | -5 | 22 | 34 | 24 |
| Netto Indkomst Før Ekstra Ting | 13501 | 10120 | 5459 | 5386 | 123 | 6225 |
| Netto Indkomst | 13501 | 4628 | 5455 | 5386 | 123 | 6225 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 13501 | 10120 | 5459 | 5386 | 123 | 6225 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 13501 | 4628 | 5455 | 5386 | 123 | 6225 |
| Fortyndelsesændring | 0 | |||||
| Fortyndet Netto Indkomst | 13501 | 4628 | 5455 | 5386 | 123 | 6225 |
| Fortyndet Vægtet Gennemsnit Aktier | 1358 | 1319 | 1308 | 1277 | 1263 | 1262 |
| Fortyndet EPS Uden Ekstraordinære Ting | 9.94183 | 7.67248 | 4.17355 | 4.2177 | 0.09739 | 4.93265 |
| Dividends per Share - Common Stock Primary Issue | 1.84 | 2.08 | 2.28 | 2.52 | 2.72 | 2.84 |
| Fortyndet Normaliseret EPS | 10.4252 | 7.82584 | 4.26568 | 4.30525 | 0.09739 | 4.93265 |
| Totale Ekstraordinære Ting | -5492 | -4 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Total omsætning | 6423 | 6217 | 7421 | 7244 | 6590 |
| Omsætning | 6423 | 6217 | 7421 | 7244 | 6590 |
| Kost af omsætning, Total | 1361 | 1390 | 1223 | 2627 | 1424 |
| Bruttofortjeneste | 5062 | 4827 | 6198 | 4617 | 5166 |
| Totale Driftsudgifter | 3533 | 3971 | 3579 | 6304 | 6393 |
| Salgs/Generelle/Admin. Udgifter, Total | 1044 | 1351 | 1190 | 1650 | 1083 |
| Forskning & Udvikling | 1117 | 1230 | 1166 | 2027 | 1186 |
| Usædvanlig Udgift (Indkomst) | 11 | 2700 | |||
| Driftsindtægter | 2890 | 2246 | 3842 | 940 | 197 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -608 | -430 | -392 | -181 | -334 |
| Andre, Netto | -18 | 1 | -12 | -15 | |
| Netto Indkomst Før Skat | 2264 | 1817 | 3438 | 759 | -152 |
| Netto Indkomst Efter Skat | 1722 | 1517 | 2586 | 376 | 12 |
| Minoritetsrente | 7 | 5 | 6 | 6 | 7 |
| Netto Indkomst Før Ekstra Ting | 1729 | 1522 | 2592 | 382 | 19 |
| Netto Indkomst | 1729 | 1522 | 2592 | 382 | 19 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 1729 | 1522 | 2592 | 382 | 19 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 1729 | 1522 | 2592 | 382 | 19 |
| Fortyndet Netto Indkomst | 1729 | 1522 | 2592 | 382 | 19 |
| Fortyndet Vægtet Gennemsnit Aktier | 1262 | 1260 | 1262 | 1262 | 1262 |
| Fortyndet EPS Uden Ekstraordinære Ting | 1.37005 | 1.20794 | 2.05388 | 0.30269 | 0.01506 |
| Dividends per Share - Common Stock Primary Issue | 0.71 | 0.71 | 0.71 | 0.71 | 0.73 |
| Fortyndet Normaliseret EPS | 1.37668 | 1.20794 | 2.05388 | 0.30269 | 1.40571 |
- Årlig
- Pr kvartal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 19588 | 31823 | 35836 | 30296 | 15996 | 14772 |
| Likvider og Kortsigtede Investeringer | 11895 | 25510 | 30089 | 24352 | 7408 | 6520 |
| Likvider & Lignende | 8229 | 7588 | 17940 | 11631 | 5997 | 5338 |
| Kortsigtede Investeringer | 3666 | 17922 | 12149 | 12721 | 1411 | 1182 |
| Totale Tilgodehavender, Netto | 4514 | 3851 | 3327 | 3582 | 4892 | 4493 |
| Accounts Receivable - Trade, Net | 4514 | 3851 | 3327 | 3582 | 4892 | 4493 |
| Total Inventory | 1587 | 801 | 814 | 922 | 1683 | 1618 |
| Prepaid Expenses | 1592 | 1649 | 1533 | 1403 | 2013 | 2141 |
| Total Assets | 56977 | 70283 | 63675 | 61627 | 68407 | 67952 |
| Property/Plant/Equipment, Total - Net | 2865 | 3295 | 4006 | 5170 | 5613 | 5663 |
| Goodwill, Net | 1172 | 4159 | 4117 | 4117 | 8108 | 8332 |
| Intangibles, Net | 8971 | 17100 | 15738 | 13786 | 33126 | 33455 |
| Long Term Investments | 20495 | 11194 | 1423 | 1488 | 502 | 1309 |
| Other Long Term Assets, Total | 3886 | 2712 | 2555 | 6770 | 5062 | 4421 |
| Total Current Liabilities | 9218 | 11635 | 10605 | 9759 | 11397 | 11610 |
| Accounts Payable | 1206 | 814 | 790 | 713 | 844 | 705 |
| Accrued Expenses | 7775 | 7271 | 6876 | 6254 | 7198 | 7600 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 2747 | 2748 | 2499 | 2757 | 1516 |
| Other Current Liabilities, Total | 237 | 803 | 191 | 293 | 598 | 1789 |
| Total Liabilities | 38090 | 49841 | 42288 | 39102 | 50205 | 46883 |
| Total Long Term Debt | 26346 | 30795 | 24574 | 22094 | 28645 | 25179 |
| Long Term Debt | 26346 | 30795 | 24574 | 22094 | 28645 | 25179 |
| Minority Interest | 476 | 59 | 147 | 125 | 19 | -5 |
| Other Liabilities, Total | 2050 | 7352 | 6962 | 7124 | 10144 | 5743 |
| Total Equity | 18887 | 20442 | 21387 | 22525 | 18202 | 21069 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 1 | 1 | 1 | 1 | 1 | 1 |
| Additional Paid-In Capital | 454 | 1264 | 2282 | 3051 | 3880 | 4661 |
| Retained Earnings (Accumulated Deficit) | 18154 | 19012 | 19024 | 19388 | 14381 | 16324 |
| Unrealized Gain (Loss) | -16 | 194 | -52 | 1 | 2 | -4 |
| Other Equity, Total | 294 | -29 | 132 | 84 | -62 | 87 |
| Total Liabilities & Shareholders’ Equity | 56977 | 70283 | 63675 | 61627 | 68407 | 67952 |
| Total Common Shares Outstanding | 1307 | 1308 | 1282 | 1266 | 1254 | 1254 |
| Other Current Assets, Total | 12 | 73 | 37 | |||
| Property/Plant/Equipment, Total - Gross | 4289 | 5197 | 6592 | 7281 | 7556 | |
| Accumulated Depreciation, Total | -994 | -1191 | -1422 | -1668 | -1893 | |
| Deferred Income Tax | 4356 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 13278 | 13925 | 13991 | 14772 | 12629 |
| Likvider og Kortsigtede Investeringer | 5666 | 6525 | 5738 | 6520 | 5325 |
| Likvider & Lignende | 4065 | 4893 | 4362 | 5338 | 4296 |
| Kortsigtede Investeringer | 1601 | 1632 | 1376 | 1182 | 1029 |
| Totale Tilgodehavender, Netto | 3925 | 4149 | 4566 | 4493 | 3787 |
| Accounts Receivable - Trade, Net | 3925 | 4149 | 4566 | 4493 | 3787 |
| Total Inventory | 1779 | 1772 | 1676 | 1618 | 1482 |
| Prepaid Expenses | 1908 | 1479 | 2011 | 2141 | 2035 |
| Total Assets | 67492 | 67984 | 67098 | 67952 | 63080 |
| Property/Plant/Equipment, Total - Net | 4990 | 4996 | 5037 | 5121 | 5253 |
| Goodwill, Net | 8334 | 8334 | 8332 | 8332 | 8314 |
| Intangibles, Net | 34781 | 34341 | 33900 | 33455 | 30331 |
| Long Term Investments | 579 | 836 | 1099 | 1309 | 1427 |
| Other Long Term Assets, Total | 5530 | 5552 | 4739 | 4963 | 5126 |
| Total Current Liabilities | 9705 | 10214 | 10245 | 11610 | 8558 |
| Accounts Payable | 570 | 608 | 585 | 705 | 583 |
| Accrued Expenses | 6661 | 6906 | 6702 | 7600 | 6483 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 2259 | 2261 | 2511 | 1516 | 1025 |
| Other Current Liabilities, Total | 215 | 439 | 447 | 1789 | 467 |
| Total Liabilities | 48540 | 48281 | 45628 | 46883 | 43153 |
| Total Long Term Debt | 27907 | 27914 | 25175 | 25179 | 25183 |
| Long Term Debt | 27907 | 27914 | 25175 | 25179 | 25183 |
| Deferred Income Tax | 4464 | 4374 | 4603 | 4356 | 3687 |
| Minority Interest | 12 | 7 | 1 | -5 | -12 |
| Other Liabilities, Total | 6452 | 5772 | 5604 | 5743 | 5737 |
| Total Equity | 18952 | 19703 | 21470 | 21069 | 19927 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 1 | 1 | 1 | 1 | 1 |
| Additional Paid-In Capital | 4092 | 4271 | 4492 | 4661 | 4867 |
| Retained Earnings (Accumulated Deficit) | 14821 | 15392 | 16903 | 16324 | 14986 |
| Unrealized Gain (Loss) | 0 | -1 | -1 | -4 | -23 |
| Other Equity, Total | 38 | 40 | 75 | 87 | 96 |
| Total Liabilities & Shareholders’ Equity | 67492 | 67984 | 67098 | 67952 | 63080 |
| Total Common Shares Outstanding | 1254 | 1254 | 1255 | 1254 | 1255 |
- Årlig
- Pr kvartal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Netto indkomst/Startlinje | 13488 | 4644 | 5460 | 5364 | 89 | 6201 |
| Likvider Fra Driftsaktiviteter | 17047 | 11898 | 8400 | 9144 | 8168 | 11384 |
| Likvider Fra Driftsaktiviteter | 177 | 233 | 226 | 255 | 288 | 329 |
| Amortization | 981 | 1053 | 1203 | 1149 | 1192 | 1721 |
| Deferred Taxes | -119 | -82 | 289 | -2098 | -214 | -116 |
| Ikke-Likvide Ting | 974 | 942 | 2161 | 5272 | 8451 | 2760 |
| Cash Taxes Paid | 2436 | 3342 | 3198 | 1793 | 2639 | 2509 |
| Likvid Rente Betalt | 885 | 1038 | 1070 | 982 | 951 | 979 |
| Ændringer i Driftskapital | 1546 | 5108 | -939 | -798 | -1638 | 489 |
| Likvider fra Investeringsaktiviteter | -11985 | -16069 | 14355 | -7817 | -14615 | -3131 |
| Kapitaludgifter | -748 | -590 | -924 | -825 | -650 | -579 |
| Andre Investerings-Cash-Flow-Ting, Total | -11237 | -15479 | 15279 | -6992 | -13965 | -2552 |
| Likvider fra Financieringsaktiviteter | -9725 | 3393 | -12318 | -7634 | 770 | -8877 |
| Financiering af Cash-Flow-Ting | -745 | -330 | -486 | -122 | -138 | -145 |
| Total Cash Dividends Paid | -2455 | -2731 | -2971 | -3222 | -3449 | -3605 |
| Udstedelse (Pensionering) af Aktier, Netto | -10793 | -720 | -2611 | -1540 | -1327 | -377 |
| Udstedelse (Pensionering) af Gæld, Netto | 4268 | 7174 | -6250 | -2750 | 5684 | -4750 |
| Udenlandsk Børs Effekter | 41 | 137 | -85 | -2 | 43 | -35 |
| Netto Ændring i Likviditet | -4622 | -641 | 10352 | -6309 | -5634 | -659 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 1722 | 3239 | 5825 | 6201 | 12 |
| Cash From Operating Activities | 2610 | 4926 | 8179 | 11384 | 1840 |
| Cash From Operating Activities | 78 | 157 | 239 | 329 | 80 |
| Amortization | 395 | 835 | 1276 | 1721 | 445 |
| Deferred Taxes | 71 | 3 | 243 | -116 | -651 |
| Non-Cash Items | 753 | 1564 | 1921 | 2760 | 3116 |
| Changes in Working Capital | -409 | -872 | -1325 | 489 | -1162 |
| Cash From Investing Activities | -2042 | -2619 | -2853 | -3131 | -1070 |
| Capital Expenditures | -165 | -284 | -423 | -579 | -247 |
| Other Investing Cash Flow Items, Total | -1877 | -2335 | -2430 | -2552 | -823 |
| Cash From Financing Activities | -2477 | -3408 | -6935 | -8877 | -1794 |
| Financing Cash Flow Items | -89 | -95 | -134 | -145 | -91 |
| Total Cash Dividends Paid | -917 | -1811 | -2711 | -3605 | -945 |
| Issuance (Retirement) of Stock, Net | -221 | -252 | -340 | -377 | -258 |
| Issuance (Retirement) of Debt, Net | -1250 | -1250 | -3750 | -4750 | -500 |
| Foreign Exchange Effects | -23 | -3 | -26 | -35 | -18 |
| Net Change in Cash | -1932 | -1104 | -1635 | -659 | -1042 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.9329 | 111403199 | -68465 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.025 | 87609319 | 3078449 | 2022-12-31 | LOW |
| Capital World Investors | Investment Advisor | 5.5242 | 68892972 | 11130228 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.7263 | 58941373 | -298977 | 2022-12-31 | LOW |
| Capital Research Global Investors | Investment Advisor | 4.3784 | 54602952 | 727482 | 2022-12-31 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 2.8775 | 35885152 | -484100 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9123 | 23848477 | 244886 | 2022-12-31 | LOW |
| Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.3088 | 16322394 | 84245 | 2023-02-28 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 1.224 | 15265179 | 12533445 | 2022-12-31 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 1.1113 | 13859234 | 761084 | 2022-12-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0416 | 12989939 | -106202 | 2022-12-31 | LOW |
| Parnassus Investments, LLC | Investment Advisor | 0.9672 | 12062537 | 295282 | 2022-12-31 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.8569 | 10686823 | -393685 | 2022-12-31 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7805 | 9733453 | -126327 | 2022-12-31 | LOW |
| Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.7772 | 9693019 | -93438 | 2022-12-31 | HIGH |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7531 | 9391729 | -99918 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.7379 | 9202568 | -820000 | 2022-12-31 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.7195 | 8972729 | -116113 | 2022-12-31 | LOW |
| California Public Employees' Retirement System | Pension Fund | 0.692 | 8630001 | -344541 | 2022-12-31 | LOW |
| Mellon Investments Corporation | Investment Advisor/Hedge Fund | 0.6788 | 8465274 | -377056 | 2022-12-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group 500000+
Handlende
92000+
Månedlkige, aktive klienter
$53000000+
Månedlig investeringsvolumen
$30000000+
Prøv nu Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
Gilead Company profile
Om Gilead Sciences
Gilead Sciences, Inc. er en biofarmaceutisk virksomhed. Virksomheden fokuserer på opdagelse, udvikling og markedsføring af lægemidler til forebyggelse og behandling af sygdomme, herunder human immundefektvirus (HIV), viral hepatitis og kræft. Virksomhedens produkter til HIV/AIDS-patienter omfatter Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild og Atripla. Virksomhedens COVID-19-produkt er Veklury. Produkterne til leversygdomme omfatter Epclusa, Harvoni, Vosevi, Vemlidy og Viread. Produkterne under hæmatologi/onkologi/celleterapi omfatter Yescarta, Tecartus, Trodelvy og Zydelig. De øvrige produkter omfatter Letairis (ambrisentan), Ranexa (ranolazin), Cayston, Jyseleca og AmBisome (amphotericin B-liposom til injektion). Selskabet sælger og distribuerer også generiske versioner af Epclusa og Harvoni i USA. Selskabet sælger og distribuerer sine produkter i USA gennem engroskæden. Virksomheden er aktiv i mere end 35 lande på verdensplan.
| Industry: | Pharmaceuticals (NEC) |
333 Lakeside Dr
FOSTER CITY
CALIFORNIA 94404-1147
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com